Navigation Links
Lilly Announces CEO Dr. John Lechleiter to Undergo Scheduled Surgery
Date:5/6/2013

INDIANAPOLIS, May 6, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that John C. Lechleiter , Ph.D., chairman, president, and chief executive officer, will undergo scheduled surgery for a dilated aorta on Monday, May 13, 2013. This condition was found during unrelated testing and has been asymptomatic. Lechleiter is expected to make a full recovery and return to his duties later this summer.

In accordance with the company's bylaws, Derica W. Rice , executive vice president, Global Services and chief financial officer, will assume the additional role of acting chief executive officer during Lechleiter's surgery and recuperation period.  Ellen R. Marram, currently the board's lead independent director, will serve as acting chairperson of the board of directors. She was appointed as lead independent director in April 2012.

Rice, 48, has more than 22 years of service with Eli Lilly and Company, including leadership roles in finance and general management. He became chief financial officer in 2006 and assumed leadership of the company's global services organization in 2010.

Marram, 66, is president of the Barnegat Group LLC, her business advisory firm, and she is also the former CEO of two consumer products companies. She has served on the Lilly board since 2002 and is also a member of the board of directors of Ford Motor Company and The New York Times Company.

"I am grateful to be under the care of a world-class medical team located right here in Indianapolis," said Lechleiter. "The board of directors and I have the utmost confidence in Ellen, Derica, and our Lilly leadership team.  The company will be in very good hands during my leave. I look forward to returning to work following my recovery."

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. C-LLY

Refer to: (317) 433-9899, egs@lilly.comEdward Sagebiel

(Logo:  http://photos.prnewswire.com/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DiversityInc Names Lilly a Top Company for Diversity
2. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
3. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
4. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
5. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
6. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
7. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
8. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
9. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
10. Lilly Diabetes Launches 8th Annual Diabetes Summer Camp Tour With Olympian Kris Freeman
11. Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... Switzerland , May 31, 2016 ... announced the initiation of a first-in-human clinical trial of ... fusion molecule - S101 is currently being developed for ... 1 study is designed to evaluate the safety and ... conducted at several sites across the United ...
(Date:5/31/2016)... The global biomaterials market is driven by the ... from chronic diseases. According to research report, "Global Biomaterials Market ... Forecasts (2016-2021) - (By Value; By Material Type - Polymer, ... By Region-North America, Europe , APAC, ROW; ... Italy , Japan , ...
(Date:5/31/2016)... , May 31, 2016 ... World Health Assembly zur Eliminierung von viraler Hepatitis ... Mitgliedsstaaten eine historische Verpflichtung eingegangen, virale Hepatitis bis ... . World Health Assembly haben sich die ... bzgl. viraler Hepatitis (Global Viral Hepatitis Strategy) zu ...
Breaking Medicine Technology:
(Date:5/31/2016)... Middletown, PA (PRWEB) , ... May 31, 2016 , ... ... in the United States, and more than 100,000 physical therapy clinics. Each physical ... for the benefit of clients. At the same time, staying afloat in a competitive ...
(Date:5/31/2016)... ... May 31, 2016 , ... Fire Door ... has joined the Fire Door Solutions’ team. Keith will serve Fire Door ... frame in-field re-labeling. He will be instrumental in developing educational curriculum and ...
(Date:5/31/2016)... ... May 31, 2016 , ... More than 80 representatives of ... Philadelphia, and the Prevent Cancer Foundation held an event on National Hepatitis Testing Day ... city of viral hepatitis, the leading cause of liver cancer. , Foundation leaders and ...
(Date:5/31/2016)... ... May 31, 2016 , ... St. Joseph ... regional health information exchange, which enables physicians at SJMC’s two hospital campuses, downtown ... other participating organizations in the exchange. SJMC’s membership in the health information exchange ...
(Date:5/31/2016)... ... May 31, 2016 , ... When MetLoop first demonstrated its ... something that contractors should have at their disposal on a daily basis. , ... Director of Contractor Programs. , As a result, Metloop and CertainTeed entered ...
Breaking Medicine News(10 mins):